Chao Yie Yang mostly deals with Biochemistry, Apoptosis, Cell biology, XIAP and Cancer research. His study focuses on the intersection of Apoptosis and fields such as Cell culture with connections in the field of Cell growth, Small molecule, Leukemia, STAT3 and Myeloid leukemia. His research integrates issues of Caspase, Activator and DNA-binding protein in his study of Cell biology.
As part of the same scientific family, Chao Yie Yang usually focuses on XIAP, concentrating on Inhibitor of apoptosis and intersecting with Pharmacology, Orally active, Bioavailability, Antagonist and Cancer cell. His Cancer research research is multidisciplinary, incorporating elements of Clinical trial, Mdm2, Mdm2 p53, Function and STAT protein. His research in Structure–activity relationship intersects with topics in Combinatorial chemistry, Smac mimetics, Protein structure and Stereochemistry.
His primary areas of study are Cancer research, Small molecule, Biochemistry, Cell growth and Apoptosis. His work carried out in the field of Cancer research brings together such families of science as Proteolysis targeting chimera, Cancer, Molecular biology, Androgen receptor and In vivo. His study in Small molecule is interdisciplinary in nature, drawing from both Ligand binding assay, Biophysics, Stereochemistry, Peptidomimetic and Binding site.
He has included themes like Cell culture, Bromodomain, BRD4, Programmed cell death and Structure–activity relationship in his Cell growth study. His Apoptosis research incorporates elements of Cancer cell, In vitro, Cytotoxicity and Cell biology. His XIAP study integrates concerns from other disciplines, such as Inhibitor of apoptosis, Smac mimetics, Combinatorial chemistry and Bivalent.
His main research concerns Cancer research, Cell growth, Cancer, Proteolysis targeting chimera and Cell culture. His Cell growth research is multidisciplinary, relying on both Mutation, IC50 and Oral administration, Pharmacology. The study incorporates disciplines such as Receptor, Protein degradation and Proteolysis in addition to Proteolysis targeting chimera.
The research on Cell biology and Biochemistry is part of his Protein degradation project. Chao Yie Yang combines subjects such as EZH2, Myeloid leukemia, Small molecule, Structure–activity relationship and In vivo with his study of Cell culture. The Myeloid leukemia study combines topics in areas such as Cancer cell, Apoptosis, Leukemia and Kinase.
His scientific interests lie mostly in Cancer research, Proteolysis targeting chimera, Cell growth, Protein degradation and Proteolysis. His studies in Cancer research integrate themes in fields like Cell culture and STAT3, STAT protein. His research on Cell culture frequently connects to adjacent areas such as In vivo.
To a larger extent, he studies Apoptosis with the aim of understanding STAT3. His Cell growth research integrates issues from Ubiquitin ligase, Receptor and Androgen receptor, LNCaP, Prostate cancer. His Protein degradation study is focused on Biochemistry in general.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
The PDBbind database: methodologies and updates.
Renxiao Wang;Xueliang Fang;Yipin Lu;Chao Yie Yang.
Journal of Medicinal Chemistry (2005)
Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins.
Guoping Wang;Zaneta Nikolovska-Coleska;Chao Yie Yang;Renxiao Wang.
Journal of Medicinal Chemistry (2006)
Design of Triazole-Stapled BCL9 α-Helical Peptides to Target the β-Catenin/B-Cell CLL/lymphoma 9 (BCL9) Protein–Protein Interaction
Steven A. Kawamoto;Adriana Coleska;Xu Ran;Han Yi.
Journal of Medicinal Chemistry (2012)
A Potent and Orally Active Antagonist (SM-406/AT-406) of Multiple Inhibitor of Apoptosis Proteins (IAPs) in Clinical Development for Cancer Treatment
Qian Cai;Haiying Sun;Yuefeng Peng;Yuefeng Peng;Jianfeng Lu.
Journal of Medicinal Chemistry (2011)
Design of Small-Molecule Peptidic and Nonpeptidic Smac Mimetics
Haiying Sun;Zaneta Nikolovska-Coleska;Chao Yie Yang;Dongguang Qian.
Accounts of Chemical Research (2008)
Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression
Bing Zhou;Jiantao Hu;Fuming Xu;Zhuo Chen.
Journal of Medicinal Chemistry (2017)
Targeting the MDM2–p53 Protein–Protein Interaction for New Cancer Therapy: Progress and Challenges
Shaomeng Wang;Yujun Zhao;Angelo Aguilar;Denzil Bernard.
Cold Spring Harbor Perspectives in Medicine (2017)
Structure-based design of potent, conformationally constrained Smac mimetics
Haiying Sun;Zaneta Nikolovska-Coleska;Chao Yie Yang;Liang Xu.
Journal of the American Chemical Society (2004)
Analysis of ligand-bound water molecules in high-resolution crystal structures of protein-ligand complexes.
Yipin Lu;Renxiao Wang;Chao Yie Yang;Shaomeng Wang.
Journal of Chemical Information and Modeling (2007)
Discovery of MD-224 as a First-in-Class, Highly Potent, and Efficacious Proteolysis Targeting Chimera Murine Double Minute 2 Degrader Capable of Achieving Complete and Durable Tumor Regression.
Yangbing Li;Jiuling Yang;Angelo Aguilar;Donna McEachern.
Journal of Medicinal Chemistry (2019)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
University of Michigan–Ann Arbor
University of Michigan–Ann Arbor
University of Michigan–Ann Arbor
National Institutes of Health
Zhejiang University
Pacific Northwest National Laboratory
Cleveland Clinic
University of Michigan–Ann Arbor
Cleveland Clinic
Chinese Academy of Sciences
University of California, Davis
Iowa State University
Brookings Institution
Misapplied Sciences, Inc.
Spanish National Research Council
North Carolina State University
Salk Institute for Biological Studies
California Institute of Technology
University of California, San Diego
Aristotle University of Thessaloniki
Université Laval
University of Tübingen
Hebrew University of Jerusalem
University College London
University of Nebraska Medical Center
Apache Corporation